

Thermally reversible solidification of novel ionic liquid [im]HSO₄ by self-nucleated rapid crystallization: Investigations of ionic conductivity, thermal properties, and catalytic activity

Michał Bielejewski^{*a}, Mahdi Ghorbani^{b*}, Mohammad Ali Zolfigol^{c*}, Jadwiga Tritt-Goc^a, Soheila Noura^b, Mahdi Narimani^b and Mohsen Oftadeh^b

^a*Institute of Molecular Physics, Polish Academy of Sciences, ul. M. Smoluchowskiego 17, 60-179 Poznań, Poland.*

^b*Chemistry Department, Payame Noor University, Tehran, Iran.*

^c*Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University, Hamedan, Po. Box: 6517838683, Iran.*

Electronic Supplementary Information (ESI)

*Corresponding Author:

Dr eng. Michał Bielejewski
Institute of Molecular Physics, PAS
60-179 Poznań, Poland
phone: +48 061 8695186
e-mail: bielejewski@ifmpan.poznan.pl

Mahdi Ghorbani
Chemistry Department, Payame Noor University, Tehran, Iran.
E-mail: ghorbanii.mahdi@gmail.com

Prof. Mohammad Ali Zolfigol
Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali Sina University
Hamedan, Iran
Phone: +988138282807, Fax: +988138380709

e-mail: zolfi@basu.ac.ir & mzolfigol@yahoo.com

Table of content

Figure S1. Images from nano crystal ionic liquid [im]HSO ₄	3
Figure S2. Typical dihydropyridine drugs	3
Figure S3. Molecular self-assembly of nano crystal ionic liquid [im]HSO ₄ via hydrogen bonding	4
Figure S4. The structure of nano crystal ionic liquid [im]HSO ₄	4
Figure S5. Temperature change of the [im]HSO ₄ sample during TSC measurement for repeating heating cycles at 1.2°C/min (a) and cooling cycles at ~7°C/min (b) and for different heating rates during heating cycles (c) and corresponding cooling cycles (d). Red and blue rectangles denote the temperature region of observed anomalies in σ_{DC} .	5
Figure S6. The derivative of the temperature dependence of the direct current conductivity σ_{DC} registered for [im]HSO ₄ sample for heating and cooling cycles at 0.7°C/min heating rate 1 st cycle (a), at 0.7°C/min heating rate 2 nd cycle (b), at 1.2°C/min heating rate 1 st (c), at 1.5°C/min heating rate 1 st (d), at 2.0°C/min heating rate 1 st (e).	6
Figure S7. The temperature dependence of activation energy of the conduction process registered for IL1 sample for heating and cooling cycles at 0.7°C/min heating rate 1 st cycle (a), at 0.7°C/min heating rate 2 nd cycle (b), at 1.2°C/min heating rate 1 st cycle (c), at 1.5°C/min heating rate 1 st (d), at 2.0°C/min heating rate 1 st (e).	7
Figure S8. The temperature dependence of the direct current conductivity σ_{DC} registered for [im]HSO ₄ sample at 0.7°C/min and 1.2°C/min heating rates (a) and corresponding cooling stages (b). The solid lines represents the best fits of Eq. (2) and dashed lines the best fits of Eq. (3) to the experimental data recorded in heating and cooling stages. The rectangles denote the regions where the anomalies were observed.	8
Figure S9. Spectra data of compounds	9
Table S1. The theoretical physical magnitudes extracted from the best fit of the Arrhenius-type and VFT-type equations (Eq. 2 and Eq. 3) to the experimental data during heating stage.	8
Table S2. The theoretical physical magnitudes extracted from the best fit of the Arrhenius-type equations (Eq. 2) to the experimental data during cooling stage.	8




Figure S1. Images from nano crystal ionic liquid [im]HSO₄




Figure S2. Typical dihydropyridine drugs




Figure S3. Molecular self-assembly of nano crystal ionic liquid [im]HSO₄ via hydrogen bonding




Figure S4. The structure of nano crystal ionic liquid [im]HSO₄




Figure S5. Temperature change of the [im]HSO₄ sample during TSC measurement for repeating heating cycles at 1.2°C/min (a) and cooling cycles at ~7°C/min (b) and for different heating rates during heating cycles (c) and corresponding cooling cycles (d). Red and blue rectangles denote the temperature region of observed anomalies in σ_{DC} .




Figure S6. The derivative of the temperature dependence of the direct current conductivity σ_{DC} registered for [im]HSO₄ sample for heating and cooling cycles at 0.7°C/min heating rate 1st cycle (a), at 0.7°C/min heating rate 2nd cycle (b), at 1.2°C/min heating rate 1st(c), at 1.5°C/min heating rate 1st(d), at 2.0°C/min heating rate 1st(e).




Figure S7. The temperature dependence of activation energy of the conduction process registered for IL1 sample for heating and cooling cycles at 0.7°C/min heating rate 1st cycle (a), at 0.7°C/min heating rate 2nd cycle (b), at 1.2°C/min heating rate 1st cycle (c), at 1.5°C/min heating rate 1st(d), at 2.0°C/min heating rate 1st(e).




Figure S8. The temperature dependence of the direct current conductivity σ_{DC} registered for [im]HSO₄ sample at 0.7°C/min and 1.2°C/min heating rates (a) and corresponding cooling stages (b). The solid lines represents the best fits of Eq. (2) and dashed lines the best fits of Eq. (3) to the experimental data recorded in heating and cooling stages. The rectangles denote the regions where the anomalies were observed.

Table S1. The theoretical physical magnitudes extracted from the best fit of the Arrhenius-type and VFT-type equations (Eq. 2 and Eq. 3) to the experimental data during heating stage.

heating stage					
	Arrhenius		Vogel-Fulcher-Tamman		
heating rate	E_a (kJ/mol)	σ_∞ (mS/cm)	E_a (kJ/mol)	σ_∞ (mS/cm)	T_g (K)
0.7 °C/min	36.3	1.65E7	3.9	1387	207.2
1.2 °C/min	36.2	1.39E7	3.4	1153	218.2
1.5 °C/min	30.6	1.57E6	2.7	788	236.6
2.0 °C/min	30.3	1.40E6	2.8	887	236.9


Table S2. The theoretical physical magnitudes extracted from the best fit of the Arrhenius-type equations (Eq. 2) to the experimental data during cooling stage.


cooling stage				
	Arrhenius I		Arrhenius II	
cooling rate	E_a (kJ/mol)	σ_∞ (mS/cm)	E_a (kJ/mol)	σ_∞ (mS/cm)
~7 °C/min	37.9	3.38E7	26.6	4.22E5
~7 °C/min	37.1	2.30E7	26.8	4.43E5
~7 °C/min	36.4	2.01E7	24.4	1.89E5

~7 °C/min	41.7	1.66E8	22.6	1.04E5
-----------	------	--------	------	--------

Ethyl 4-(4-bromophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate


White solid, ¹H NMR (300 MHz, DMSO-d₆): δ (ppm) 0.83 (s, 3H), 0.99 (s, 3H), 1.10 (t, J = 6.9 Hz, 3H), 1.96 (d, J = 16.0 Hz, 1H), 2.16 (d, J = 16.1 Hz, 1H), 2.29 (s, 3H), 2.38-2.49 (m, 2H), 3.97 (q, J = 7.0 Hz, 2H), 4.84 (s, 1H), 7.11 (d, J = 7.2 Hz, 2H), 7.37 (d, J = 7.2 Hz, 2H), 9.09 (s, 1H); ¹³C NMR (75 MHz, DMSO-d₆): δ (ppm) 14.6, 18.8, 26.9, 29.5, 32.6, 36.2, 50.6, 59.5, 103.5, 110.1, 119.1, 130.2, 131.0, 145.8, 147.4, 150.0, 167.1, 194.7.






Ethyl 4-(p-tolyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylat


White solid, ^1H NMR (500 MHz, CDCl_3): δ (ppm) 0.96 (s, 3H), 1.08 (s, 3H), 1.24 (t, $J = 7.1$ Hz, 3H), 2.15-2.31 (m, 7H), 2.35 (s, 3H), 4.09 (q, $J = 7.1$ Hz, 2H), 5.04 (s, 1H), 6.76 (s, 1H), 7.02 (d, $J = 7.8$ Hz, 2H), 7.21 (d, $J = 7.8$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ (ppm) 14.7, 19.7, 21.5, 27.6, 29.8, 33.1, 36.6, 41.3, 51.2, 60.2, 106.6, 112.4, 128.3, 129.0, 135.8, 143.9, 144.7, 149.3, 167.9, 196.1.






4-(4-methoxyphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate


White solid, ^1H NMR (300 MHz, DMSO-d_6): δ (ppm) 0.85 (s, 3H), 1.00 (s, 3H), 1.14 (t, $J = 7.0$ Hz, 3H), 1.96 (d, $J = 16.0$ Hz, 1H), 2.15 (d, $J = 16.1$ Hz, 1H), 2.27 (s, 3H), 2.37-2.49 (m, 2H), 3.66 (s, 3H), 3.97 (q, $J = 7.0$ Hz, 2H), 4.79 (s, 1H), 6.73 (d, $J = 8.3$ Hz, 2H), 7.05 (d, $J = 8.3$ Hz, 2H), 8.99 (s, 1H); ^{13}C NMR (75 MHz, DMSO-d_6): δ (ppm) 14.6, 18.7, 26.9, 29.6, 32.6, 35.4, 50.6, 55.3, 59.4, 104.4, 110.7, 113.5, 128.8, 140.5, 145.1, 149.7, 157.7, 167.4, 194.






Ethyl 4-(2-nitrophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate


yellow solid, ^1H NMR: (400 MHz CDCl_3): δ (ppm) 0.91 (s, 3H), 1.09 (q, $J=7.2$, 3H), 1.61 (s, 3H), 2.07 (d, $J=10.4$, 1H), 2.18 (d, $J=7.2$, 1H), 2.30 (d, $J=7.6$, 1H), 2.29 (s, 1H), 2.38 (s, 3H), 3.97-4.10 (m, 2H), 5.87 (s, 1H), 5.91 (s, 1H), 7.23 (t, $J=8$, 1H), 7.44 (t, $J=7.6$, 1H), 7.50 (d, $J=7.6$, 1H), 7.74 (d, $J=8$, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.0, 19.5, 27.3, 29.0, 32.6, 33.1, 41.2, 50.4, 60.0, 105.3, 111.6, 124.0, 126.7, 131.2, 132.1, 141.2, 144.0, 148.0, 148.9, 167.1, 195.1






Ethyl 4-(4-hydroxyphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate


White solid, ^1H NMR (300 MHz, DMSO-d_6): δ (ppm) 0.86 (s, 3H), 1.00 (s, 3H), 1.14 (t, $J = 7.0$ Hz, 3H), 1.96 (d, $J = 16.0$ Hz, 1H), 2.15 (d, $J = 16.1$ Hz, 1H), 2.26 (s, 3H), 2.36-2.49 (m, 2H), 3.96 (q, $J = 7.0$ Hz, 2H), 4.74 (s, 1H), 6.56 (d, $J = 8.1$ Hz, 2H), 6.93 (d, $J = 8.1$ Hz, 2H), 8.94 (s, 1H), 9.01 (s, 1H); ^{13}C NMR (75 MHz, DMSO-d_6): δ (ppm) 14.6, 18.7, 26.9, 29.6, 32.6, 35.3, 50.8, 59.4, 104.6, 110.8, 114.9, 128.8, 138.9, 144.8, 149.6, 155.7, 167.5, 194.7.






Ethyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate



White solid, ^1H NMR (500 MHz, CDCl_3): δ (ppm) 0.92 (s, 3H), 1.10 (s, 3H), 1.19 (t, $J = 7.1$ Hz, 3H), 2.16 (d, $J = 16.4$ Hz, 2H), 2.24-2.29 (Distorted AB system, 2H), 2.41 (s, 3H), 4.07 (q, $J = 7.1$ Hz, 2H), 5.18 (s, 1H), 6.68 (s, 1H), 7.51 (d, $J = 8.5$ Hz, 2H), 8.09 (d, $J = 8.5$ Hz, 2H); ^{13}C NMR (125 MHz, CDCl_3): δ (ppm) 14.6, 19.8, 27.5, 29.8, 33.1, 37.7, 41.3, 51.0, 60.5, 105.3, 111.4, 123.7, 129.4, 145.0, 146.6, 149.6, 154.9, 167.3, 195.9.






Ethyl 4-(2,5-dimethoxyphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate


White solid; ^1H NMR (400 MHz, DMSO-d_6): δ (ppm) 0.86 (s, 3H, —CH₃), 1.00 (s, 3H, —CH₃), 1.14 (t, 3H, J = 7.2 Hz, —CH₃), 1.93 (d, 1H, J = 8.0 Hz, —CH₂), 2.14 (d, 1H, J = 8.2 Hz, —CH₂), 2.18 (s, 3H, —CH₃), 2.26 (d, 1H, J = 8.6 Hz, —CH₂), 2.42 (d, 1H, J = 8.6 Hz, —CH₂), 3.63 (s, 3H, —CH₃), 3.64 (s, 3H, —CH₃), 3.94 (q, 2H, J = 5.4 Hz, —CH₂), 4.99 (s, 1H, —CH), 6.62 (d, 1H, J = 3.2 Hz, ArH), 6.65 (d, 1H, J = 2.4 Hz, ArH), 6.77 (s, 1H, ArH), 8.97 (s, 1H, —NH); ^{13}C NMR (100 MHz, DMSO-d_6): δ (ppm) 14.6, 18.5, 26.7, 29.8, 32.5, 33.5, 40.1, 50.8, 55.5, 56.3, 59.3, 103.3, 109.0, 111.3, 112.4, 117.3, 136.6, 144.5, 150.5, 152.0, 153.0, 167.7, 194.3






Ethyl 4-(3-ethoxy-4-hydroxyphenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-Carboxylate.



white solid, ^1H NMR: (400 MHz, DMSO-d_6): δ (ppm) 1.00 (s, 3H), 1.14 (t, $J = 6.8$), 1.28 (t, $J = 6.4$), 1.90 (s, 3H), 1.97 (d, $J = 14$, 1H), 2.16 (d, $J = 15.6$, 1H), 2.26 (d, $J = 12$, 1H), 2.38 (s, 3H), 2.42 (s, 1H), 3.89 (t, $J = 7.2$, 2H), 3.98 (q, $J = 7.6$, 2H), 4.72 (s, 1H), 5.57 (d, $J = 7.6$, 1H), 6.49 (d, $J = 7.6$, 1H), 6.67 (s, 1H), 8.55 (s, 1H), 8.99 (s, 1H); ^{13}C NMR (100MHz, DMSO-d_6): δ (ppm) 19.5, 27.1, 29.4, 32.7, 35.4, 41.1, 50.7, 51.0, 55.1, 106.0, 112.5, 113.3, 128.7, 139.3, 143.3, 147.5, 157.7, 167.9, 195.5






Ethyl 2,7,7-trimethyl-4-(naphthalen-1-yl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate


white solid, ^1H NMR: (400 MHz, CDCl_3): δ (ppm) 0.89 (t J = 8.8, 3H) 1.04 (s 3H) 2.04 (s 3H CH_3) 2.09 (d J = 13.6, 1H) 2.16 (s 1H) 2.21 (d J = 9.6, 1H) 2.26 (s 1H) 2.36 (s 3H) 3.75- 3.96 (m 2H) 5.83 (s 1H) 6.19 (s 1H) 7.28 (s 1H) 7.34 (t J = 7.6, 1H) 7.434 (t J = 7.6 1H) 7.56 (t J = 7.6, 1H) 7.63 (d J = 8 1H) 7.75 (d J = 8, 1H) 8.82 (d J = 8.8, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 13.9 19.3 27.1 29.3 31.7 32.5 41.0 50.5 59.6 107.8 113.4 125.2 125.8 126.6 126.8 127.7 131.1 133.2 142.7 146.0 147.6 167.5 195.6






Ethyl 4-(4-chloro-3-nitrophenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate

White solid, ^1H NMR: (400 MHz, CDCl_3): δ (ppm) 0.97 (s, 3H), 1.11 (s, 3H), 1.22 (t, $J=7.2$, 3H), 2.17 (d, $J=16.4$, 1H), 2.22 (d, $J=16.8$, 2H), 2.36 (s, 1H), 2.42 (s, 3H), 4.09 (q, $J=7.2$, 2H), 5.11 (s, 1H), 5.89 (s, 1H), 7.55 (d, $J=2$, 1H), 7.57 (d, $J=1.6$, 1H), 7.77 (d, $J=1.6$, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ (ppm) 14.1, 19.6, 27.1, 29.3, 32.8, 36.5, 41.1, 50.5, 60.1, 104.8, 111.1, 124.4, 125.0, 131.0, 133.3, 144.3, 147.5, 148.2, 166.6, 195.2.





Ethyl 4-(biphenyl-4-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8- hexahydroquinoline-3-carboxylate

White solid; ^1H NMR (400 MHz, DMSO-d_6): δ (ppm) 0.87 (s, 3H, $-\text{CH}_3$), 1.02 (s, 3H, $-\text{CH}_3$), 1.17 (t, 3H, $J = 7.0$ Hz, $-\text{CH}_3$), 2.02 (d, 1H, $J = 8.8$ Hz, $-\text{CH}_2$), 2.20 (d, 1H, $J = 8.2$ Hz, $-\text{CH}_2$), 2.30 (s, 3H, $-\text{CH}_3$), 2.34 (d, 1H, $J = 7.6$ Hz, $-\text{CH}_2$), 2.46 (d, 1H, $J = 8.6$ Hz, $-\text{CH}_2$), 4.02 (q, 2H, $J = 7.2$ Hz, $-\text{CH}_2$), 4.90 (s, 1H, $-\text{CH}$), 7.25 (d, 100 2H, $J = 8.4$ Hz, ArH), 7.34 (t, 1H, $J = 7.8$ Hz, ArH), 7.42 (d, 2H, $J = 8.0$ Hz, ArH), 7.50 (d, 2H, $J = 8.4$ Hz, ArH), 7.61 (d, 2H, $J = 9.2$ Hz, ArH), 9.10 (s, 1H, $-\text{NH}$); ^{13}C NMR (100 MHz, DMSO-d_6): δ 14.6, 18.8, 27.1, 29.5, 32.7, 36.0, 50.7, 59.6, 103.9, 110.3, 126.6, 126.9, 127.5, 105128.5, 129.3, 138.1, 140.1, 145.5, 147.3, 150.1, 167.3, 194.8

